H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71 (2021) 209-249.
 J.J. Lee, S. Park, H. Park, S. Kim, J. Lee, J. Lee, J. Youk, K. Yi, Y. An, I.K. Park, C.H. Kang, D.H. Chung, T.M. Kim, Y.K. Jeon, D. Hong, P.J. Park, Y.S. Ju, and Y.T. Kim, Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma. Cell 177 (2019) 1842-1857 e21.
 C. Zappa, and S.A. Mousa, Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5 (2016) 288-300.
 S. Zaccara, R.J. Ries, and S.R. Jaffrey, Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol 20 (2019) 608-624.
 X.Y. Chen, J. Zhang, and J.S. Zhu, The role of m(6)A RNA methylation in human cancer. Mol Cancer 18 (2019) 103.
 Y. Yang, P.J. Hsu, Y.S. Chen, and Y.G. Yang, Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res 28 (2018) 616-624.
 G. Yang, Z. Sun, and N. Zhang, Reshaping the role of m6A modification in cancer transcriptome: a review. Cancer Cell Int 20 (2020) 353.
 R.I.N. Khan, and W.A. Malla, m(6)A modification of RNA and its role in cancer, with a special focus on lung cancer. Genomics 113 (2021) 2860-2869.
 F. Li, H. Wang, H. Huang, L. Zhang, D. Wang, and Y. Wan, m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma. Front Genet 11 (2020) 994.
 L. Yang, S. Wu, C. Ma, S. Song, F. Jin, Y. Niu, and W.M. Tong, RNA m(6)A Methylation Regulators Subclassify Luminal Subtype in Breast Cancer. Front Oncol 10 (2020) 611191.
 J. Li, W. Wang, Y. Zhou, L. Liu, G. Zhang, K. Guan, X. Cui, X. Liu, M. Huang, G. Cui, and R. Sun, m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma. Front Cell Dev Biol 9 (2021) 687756.
 Y. Du, Y. Ma, Q. Zhu, T. Liu, Y. Jiao, P. Yuan, and X. Wang, An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. Front Pharmacol 12 (2021) 707930.
 W. Chong, L. Shang, J. Liu, Z. Fang, F. Du, H. Wu, Y. Liu, Z. Wang, Y. Chen, S. Jia, L. Chen, L. Li, and H. Chen, m(6)A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer. Theranostics 11 (2021) 2201-2217.
 H. Zhou, M. Zheng, M. Shi, J. Wang, Z. Huang, H. Zhang, Y. Zhou, and J. Shi, Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment. BMC Cancer 21 (2021) 938.
 Y. Jin, Z. Wang, D. He, Y. Zhu, X. Hu, L. Gong, M. Xiao, X. Chen, Y. Cheng, and K. Cao, Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma. Front Immunol 12 (2021) 637933.
 J. Zhong, Z. Liu, C. Cai, X. Duan, T. Deng, and G. Zeng, m(6)A modification patterns and tumor immune landscape in clear cell renal carcinoma. J Immunother Cancer 9 (2021).
 W. Dai, Y. Li, S. Mo, Y. Feng, L. Zhang, Y. Xu, Q. Li, and G. Cai, A robust gene signature for the prediction of early relapse in stage I-III colon cancer. Mol Oncol 12 (2018) 463-475.
 S. Liu, Q. Li, K. Chen, Q. Zhang, G. Li, L. Zhuo, B. Zhai, X. Sui, X. Hu, and T. Xie, The emerging molecular mechanism of m(6)A modulators in tumorigenesis and cancer progression. Biomed Pharmacother 127 (2020) 110098.
 A.E. Arguello, A.N. DeLiberto, and R.E. Kleiner, RNA Chemical Proteomics Reveals the N(6)-Methyladenosine (m(6)A)-Regulated Protein-RNA Interactome. J Am Chem Soc 139 (2017) 17249-17252.
 Y. Li, J. Xiao, J. Bai, Y. Tian, Y. Qu, X. Chen, Q. Wang, X. Li, Y. Zhang, and J. Xu, Molecular characterization and clinical relevance of m(6)A regulators across 33 cancer types. Mol Cancer 18 (2019) 137.
 Z. Zhou, J. Lv, H. Yu, J. Han, X. Yang, D. Feng, Q. Wu, B. Yuan, Q. Lu, and H. Yang, Mechanism of RNA modification N6-methyladenosine in human cancer. Mol Cancer 19 (2020) 104.
 Y. Niu, X. Zhao, Y.S. Wu, M.M. Li, X.J. Wang, and Y.G. Yang, N6-methyl-adenosine (m6A) in RNA: an old modification with a novel epigenetic function. Genomics Proteomics Bioinformatics 11 (2013) 8-17.
 M.D. Wilkerson, and D.N. Hayes, ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26 (2010) 1572-3.
 Y. He, Z. Jiang, C. Chen, and X. Wang, Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res 37 (2018) 327.
 A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102 (2005) 15545-50.
 P. Charoentong, F. Finotello, M. Angelova, C. Mayer, M. Efremova, D. Rieder, H. Hackl, and Z. Trajanoski, Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep 18 (2017) 248-262.
 J. Chen, C. Wang, W. Fei, X. Fang, and X. Hu, Epitranscriptomic m6A modification in the stem cell field and its effects on cell death and survival. Am J Cancer Res 9 (2019) 752-764.
 L.P. Vu, B.F. Pickering, Y. Cheng, S. Zaccara, D. Nguyen, G. Minuesa, T. Chou, A. Chow, Y. Saletore, M. MacKay, J. Schulman, C. Famulare, M. Patel, V.M. Klimek, F.E. Garrett-Bakelman, A. Melnick, M. Carroll, C.E. Mason, S.R. Jaffrey, and M.G. Kharas, The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med 23 (2017) 1369-1376.
 Y. Li, J. Gu, F. Xu, Q. Zhu, Y. Chen, D. Ge, and C. Lu, Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma. Brief Bioinform 22 (2021).
 L.A. Bach, What Happened to the IGF Binding Proteins? Endocrinology 159 (2018) 570-578.
 F. Zheng, Q. Tang, X.H. Zheng, J. Wu, H. Huang, H. Zhang, and S.S. Hann, Inactivation of Stat3 and crosstalk of miRNA155-5p and FOXO3a contribute to the induction of IGFBP1 expression by beta-elemene in human lung cancer. Exp Mol Med 50 (2018) 1-14.
 J. Dong, Y. Zeng, P. Zhang, C. Li, Y. Chen, Y. Li, and K. Wang, Serum IGFBP2 Level Is a New Candidate Biomarker of Severe Malnutrition in Advanced Lung Cancer. Nutr Cancer 72 (2020) 858-863.
 F. Tas, E. Bilgin, D. Tastekin, K. Erturk, and D. Duranyildiz, Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer. Biomed Rep 4 (2016) 609-614.
 X. Li, Z. Feng, R. Wang, J. Hu, X. He, and Z. Shen, Expression Status and Prognostic Value of m(6)A RNA Methylation Regulators in Lung Adenocarcinoma. Life (Basel) 11 (2021).
 X. Wu, H. Sheng, L. Wang, P. Xia, Y. Wang, L. Yu, W. Lv, and J. Hu, A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients. Aging (Albany NY) 13 (2021) 10034-10057.
 H. Wang, X. Zhao, and Z. Lu, m(6)A RNA Methylation Regulators Act as Potential Prognostic Biomarkers in Lung Adenocarcinoma. Front Genet 12 (2021) 622233.
 Z. Zhuang, L. Chen, Y. Mao, Q. Zheng, H. Li, Y. Huang, Z. Hu, and Y. Jin, Diagnostic, progressive and prognostic performance of m(6)A methylation RNA regulators in lung adenocarcinoma. Int J Biol Sci 16 (2020) 1785-1797.
 J. Li, K.T. Byrne, F. Yan, T. Yamazoe, Z. Chen, T. Baslan, L.P. Richman, J.H. Lin, Y.H. Sun, A.J. Rech, D. Balli, C.A. Hay, Y. Sela, A.J. Merrell, S.M. Liudahl, N. Gordon, R.J. Norgard, S. Yuan, S. Yu, T. Chao, S. Ye, T.S.K. Eisinger-Mathason, R.B. Faryabi, J.W. Tobias, S.W. Lowe, L.M. Coussens, E.J. Wherry, R.H. Vonderheide, and B.Z. Stanger, Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49 (2018) 178-193 e7.
 F. Wu, Y. Cheng, L. Wu, W. Zhang, W. Zheng, Q. Wang, H. Cao, X. Pan, and W. Tang, Emerging Landscapes of Tumor Immunity and Metabolism. Front Oncol 10 (2020) 575037.